FDA Flags High-Risk Issue with Erbe Flexible Cryoprobes
The FDA’s Center for Devices and Radiological Health (CDRH) has issued an Early Alert regarding a potentially high-risk issue involving certain flexible cryoprobes manufactured by Erbe USA.
Issue Overview
Erbe USA has identified a defect in specific cryoprobe models that may cause the device to rupture or burst during activation. The root cause of the issue is insufficient adhesive applied during manufacturing, resulting in excessive internal pressure leading to device failure
Risk to Patients and Users
A device rupture may result in a loud explosive sound, tinnitus or hearing loss (temporary or permanent) and burns or physical injury to patients or healthcare personnel.
As of February 24, five serious injuries were reported and no deaths were reported.
Required Actions (Immediate)
The FDA and manufacturer are advising all users to immediately discontinue use of affected devices, identify and quarantine impacted lot numbers, notify all relevant personnel and downstream users, and ensure redistributed products are tracked and recalled
Device Context
Flexible cryoprobes are used in interventional procedures for tissue destruction (cryotherapy), removal of foreign bodies, clots, and mucus plugs, tumor debulking, and biopsy support.
Given their use in critical airway and tissue procedures, device integrity is essential.
Regulatory Status
This is an FDA Early Alert, indicating a potentially high-risk issue under active review. Additional updates may follow as more data becomes available.
MDP Insight: What This Means for Manufacturers and Providers
This alert highlights several important regulatory and quality considerations.
Manufacturing Controls Matter
A seemingly minor issue, adhesive application, resulted in a high-risk device failure mode. This reinforces the importance of process validation, supplier/material controls, and production consistency.
Risk Management Must Address Use Conditions
Devices used under pressure or extreme conditions require robust design controls that include a failure mode analysis.
Field Action Execution Is Critical
Effective recall/notification processes must ensure rapid identification of affected lots, clear communication across distribution chains, and user awareness at the point of care.
Bottom Line
This event underscores how manufacturing variability can translate directly into patient risk, particularly in interventional devices. For manufacturers, it is a reminder that small process deviations can have large clinical consequences, and postmarket surveillance and rapid response systems are essential.
Download a list of recalled product lot numbers
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...